These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22012605)

  • 21. Development of assay for determining free IgE levels in serum from patients treated with omalizumab.
    Ito R; Gon Y; Nunomura S; Atsuta R; Harada N; Hattori T; Maruoka S; Okayama Y; Ra C; Hashimoto S
    Allergol Int; 2014 May; 63 Suppl 1():37-47. PubMed ID: 24809374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
    Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
    Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
    Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
    Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.
    Lowe PJ; Georgiou P; Canvin J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):68-77. PubMed ID: 25497995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
    Rottem M
    J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between pretreatment specific IgE and the response to omalizumab therapy.
    Wahn U; Martin C; Freeman P; Blogg M; Jimenez P
    Allergy; 2009 Dec; 64(12):1780-7. PubMed ID: 19627273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
    Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
    Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens].
    Sugino Y; Sanda R; Takagi Y; Kato M; Ohta A; Okumura J; Nagai H
    Arerugi; 2010 Nov; 59(11):1572-9. PubMed ID: 21119303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab).
    Hamilton RG
    J Allergy Clin Immunol; 2006 Apr; 117(4):759-66. PubMed ID: 16630931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.